DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective study to determine the incidence, morbidity, mortality and predisposing
factors for the reactivation of hepatitis B virus replication during direct anti-HCV
treatment of HCV/HBV co-infection patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Humanity & Healthy GI and Liver Centre Humanity and Health Research Centre
Collaborators:
Beijing 302 Hospital Nanfang Hospital of Southern Medical University
Treatments:
Entecavir Hepatitis C Antibodies Ledipasvir Ledipasvir, sofosbuvir drug combination Ritonavir Sofosbuvir Tenofovir